# ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

> **NCT06699576** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 448 (estimated)

## Conditions studied

- Osteosarcoma
- Soft Tissue Sarcoma (STS)

## Interventions

- **DRUG:** HS-20093
- **DRUG:** Anlotinib
- **DRUG:** Epirubicin
- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT06699576
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 448 (ESTIMATED)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699576, "ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06699576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*